$RLFTF News

Last published 2y ago

2y agoETON RLFTFEton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for PhenylketonuriaGlobeNewswirePKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call pointTransaction is expected to be accretive to 2024 earningsEstimated peak
3y agoRLFTF RLFTYRelief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023ACCESS NewswireAcer Therapeutics reports data from a survey of UCD healthcare providers show taste and odor are the most important attributes when considering treatment options and adherenceGENEVA, SWITZERLAND / ACCESSWIRE / March 22,
3y agoRLFTF RLFTYRelief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual MeetingACCESS NewswireThe results of the preclinical study demonstrate improved muscle anabolism and function with a prolonged-release amino acid supplement using Physiomimic Technology™GENEVA, SWITZERLAND / ACCESSWIRE / March 17, 2023
3y agoRLFTF RLFTYRelief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE BarsACCESS NewswirePaolo Galfetti, chief operating officer of Relief Therapeutics and chief executive officer of APR Applied Pharma Research SA, shares his family's rare story of living with phenylketonuriaGENEVA, SWITZERLAND / ACCESSWIRE
3y agoRLFTF RLFTYRelief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis BullosaACCESS NewswireGENEVA, SWITZERLAND / ACCESSWIRE / February 14, 2023 / RELIEF THERAPEUTICS Holding SA , a biopharmaceutical company
3y agoRLFTF RLFTYRelief Therapeutics Provides an Update on its Financing StrategyACCESS NewswireGENEVA, SWITZERLAND / ACCESSWIRE / February 8, 2023 / RELIEF THERAPEUTICS Holding SA , today provided an update on its financing strategy and the decision to
3y agoACER RLFTFAcer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle DisordersGlobeNewswireNew FDA-approved formulation for patients living with urea cycle disorders $42.5 million of non-dilutive debt funding available to Acer that, if drawn, would extend cash runway into H2 2023 NEWTON, Mass. and GENEVA,
3y agoNRXP RLFTF RLFTYRelief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement AgreementsPR NewswireAd hoc announcement pursuant to Art. 53 LR GENEVA and RADNOR, Pa., Dec. 20, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), and NRx Pharmaceuticals, Inc.
3y agoRLFTD RLFTF RLFTYAPR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film FestivalPR NewswireGENEVA, Nov. 21, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB:RLFTF) (RLFTD) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing
3y agoNRXP RLFTD RLFTF RLFTYRelief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement AgreementsPR NewswireAd hoc announcement pursuant to Art. 53 LR GENEVA and RADNOR, Pa., Nov. 14, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTD)) ("Relief"), and NRx Pharmaceuticals, Inc.
4y agoRLFTF RLFTYRelief Announces Exclusive Distributor for PKU GOLIKE in the U.S.ACCESS NewswireLeading Provider of Food for Special Medical Purposes to Help Maximize Patient Access in Support of PKU GOLIKE ® U.S. Launch GENEVA, SWITZERLAND / ACCESSWIRE / October 6, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relie
4y agoACER RLFTFAcer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium BenzoateGlobeNewswireNEWTON, Mass. and GENEVA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER) (Acer) and RELIEF THERAPEUTICS Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) (Relief) today announced that the US Patent and Trademark Office (USPTO) has iss
4y agoRLFTF RLFTYRelief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of ChicagoACCESS NewswireProfessor Amy Paller, M.D., will serve as Principal Investigator to evaluate Nexodyn for the management of colonized dystrophic and junctional Epidermolysis Bullosa wounds, an important unmet need in this group of rare inherited skin diseases that affect
4y agoRLFTF RLFTYRelief Reports Half-Year 2022 Results and Provides Corporate UpdateACCESS NewswireGENEVA, SWITZERLAND / ACCESSWIRE / September 15, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company seeking to provide patients therapeutic benefit from selected speci
4y agoRLFTF RLFTYRelief Therapeutics to Participate in the 22nd Annual Biotech in Europe ForumACCESS NewswireGENEVA, SWITZERLAND / ACCESSWIRE / September 12, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company seeking to provide patients therapeutic benefit from selected speci
4y agoRLFTF RLFTYRelief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceACCESS NewswireGENEVA, SWITZERLAND / ACCESSWIRE / September 7, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company seeking to provide patients therapeutic benefit from selected specia
4y agoRLFTF RLFTYRelief Therapeutics Files Registration Statement on form F-1 with the U.S. Securities and Exchange CommissionACCESS NewswireGENEVA, SWITZERLAND / ACCESSWIRE / August 24, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), today announced today that it has filed a Registration Statement on Form F-1 under the Securities Act of 1933 with the U.S
4y agoNRXP RLFTF RLFTYRELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE TENTATIVE SETTLEMENT OF PENDING LITIGATIONPR NewswireRelease of an ad hoc announcement pursuant to Art. 53 LR GENEVA and RADNOR, Pa., Aug. 22, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) ("Relief"), and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx"), today
4y agoNRXP RLFTF RLFTYRelief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending LitigationACCESS NewswireGENEVA, SWITZERLAND and RADNOR, PA / ACCESSWIRE / August 22, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx"), today announced that they have agreed to a tentative s
4y agoRLFTF RLFTYRelief Therapeutics Appoints David McCullough as Head of U.S. Market AccessACCESS NewswireExperienced Leader in Market Access to Bolster Relief's U.S. Commercial Operations GENEVA, SWITZERLAND / ACCESSWIRE / August 17, 2022 / RELIEF THERAPEUTICS Holding SA ((SIX:RLF, OTCQB:RLFTF, RLFTY)) (" Relief "), a biopharmaceutical company seeking to p
4y agoACER RLFTFRelief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine DiseaseGlobeNewswireGENEVA, Switzerland and NEWTON, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- RELIEF THERAPEUTICS Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) (Relief), and its collaboration partner, Acer Therapeutics Inc. (NASDAQ:ACER) (Acer), today announced that the Euro
4y agoRLFTF RLFTYRelief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100(R) (Aviptadil)ACCESS NewswireThis new formulation may have important clinical uses for a variety of rare lung diseases GENEVA, SWITZERLAND / ACCESSWIRE / August 3, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seek
4y agoACER RLFTFAcer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine DiseaseGlobeNewswireNEWTON, Mass. and GENEVA, Switzerland, July 28, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER) (Acer) and its collaboration partner, RELIEF THERAPEUTICS Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) (Relief), today announced the submission
4y agoACER RLFTFAcer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDsGlobeNewswireNEWTON, Mass. and GENEVA, July 28, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER) (Acer) and its collaboration partner, RELIEF THERAPEUTICS Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) (Relief), today announced the U.S. Food and Drug Admi
4y agoRLFTF RLFTYRelief Therapeutics Announces Effectiveness of Registration Statement on Form 20-FACCESS NewswireGENEVA, SWITZERLAND / ACCESSWIRE / July 21, 2022 / RELIEF THERAPEUTICS Holding SA ((SIX:RLF, OTCQB:RLFTF, RLFTY)) (" Relief ") announced today that the U.S. Securities and Exchange Commission (" SEC ") has declared effective its Registration Statement on
4y agoACER RLFTFAcer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage FormGlobeNewswireNEWTON, Mass. and GENEVA, July 08, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER) (Acer) and its collaboration partner, RELIEF THERAPEUTICS Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) (Relief), today announced that the China National Int
4y agoACER RLFTFAcer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001GlobeNewswireCiting the need to inspect a third-party contract packaging manufacturer, the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) The FDA has not raised any approvability concerns related to the efficacy, safety or ph
4y agoRLFTF RLFTYRelief Therapeutics Announces Results of Annual General Meeting of RELIEF THERAPEUTICS Holding SAACCESS NewswireGENEVA, SWITZERLAND / ACCESSWIRE / June 1, 2022 / RELIEF THERAPEUTICS Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) (" Relief " or the " Company "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high
4y agoRLFTF RLFTYRelief Provides a Corporate Update and Comments on the Recently Announced DSMB Update on the U.S. National Institutes of Health (NIH) Study of Intravenous Aviptadil in Critical COVID-19 PatientsACCESS NewswireGENEVA, SWITZERLAND / ACCESSWIRE / May 31, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet needs, today
4y agoNRXP RLFTF RLFTYRelief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19ACCESS NewswireGENEVA, SWITZERLAND / ACCESSWIRE / May 26, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF), (OTCQB:RLFTF, RLFTY))) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported
4y agoRLFTF RLFTYRelief Therapeutics Expands U.S. Commercial TeamACCESS NewswireTracy Truong and Kelli Powell Appointed Regional Clinical Specialists for the West and Northeast Regions, RespectivelySeasoned Account Managers Bring Extensive Pharmaceutical Sales Experience in Rare Diseases GENEVA, SWITZERLAND / ACCESSWIRE / May 23,
4y agoRLFTF RLFTYRelief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange CommissionACCESS NewswireGENEVA, SWITZERLAND / ACCESSWIRE / May 11, 2022 / RELIEF THERAPEUTICS Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) (" Relief "), announced today that it has filed Amendment No. 2 to its Registration Statement on Form 20-F (" Registration Statement ") with
4y agoRLFTF RLFTYRelief Therapeutics to Participate in Industry and Investor Conferences in MayACCESS NewswireGENEVA, SWITZERLAND / ACCESSWIRE / May 9, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today a
4y agoACER RLFTFAcer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International ConferenceGlobeNewswireNEWTON, Mass. and GENEVA, May 06, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) ("Relief"), today announced the presentation of data
4y agoACER RLFTF RLFTYAcer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International ConferenceACCESS NewswireNEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / May 6, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA ((SIX:RLF, OTCQB:RLFTF, RLFTY)) ("Relief"), today announced the presentation of da
4y agoRLFTF RLFTYRelief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SAACCESS NewswireGENEVA, SWITZERLAND / ACCESSWIRE / May 6, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTY) ("Relief" or the "Company"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, tod
4y agoRLFTF RLFTYRelief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R)ACCESS NewswireNotice of Allowance of Patent Application for Modified Release Orally Administered Amino Acid Formulations, Strengthens Proprietary Position in U.S. until 2036 GENEVA, SWITZERLAND / ACCESSWIRE / April 27, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(
4y agoRLFTF RLFTYRelief Therapeutics Appoints Drew Cronin-Fine as Executive Director, Head of U.S. MarketingACCESS NewswireProven Pharmaceutical Marketing Leader Brings Extensive Experience in Rare Diseases, Digital Innovation and New Product Launches to Relief's U.S. Commercial Team GENEVA, SWITZERLAND / ACCESSWIRE / April 26, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)
4y agoNRXP RLFTF RLFTYRelief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for AviptadilACCESS NewswireRelief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil in a Subgroup of Patients with Critical COVID-19 with Respiratory Failure that were also Treated with Remdesivir and Continued to Pr
4y agoACER RLFTFAcer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual MeetingGlobeNewswireNEWTON, Mass. and GENEVA, April 12, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) ("Relief"), today announced the presentation of da
4y agoACER RLFTF RLFTYAcer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual MeetingACCESS NewswireNEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / April 12, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), today announced the presentatio
4y agoRLFTF RLFTYRelief Therapeutics Reports Execution of Stipulation with NeuroRx and Jonathan Javitt to Continue Mediation ProcessACCESS NewswireGENEVA, SWITZERLAND / ACCESSWIRE / April 5, 2022 / RELIEF THERAPEUTICS Holding SA ((SIX:RLF, OTCQB:RLFTF, RLFTY)) (" Relief "), today reported that it has entered into a stipulation to stay the proceedings in its pending litigation with NeuroRx, Inc. and
4y agoRLFTF RLFTYRelief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'ACCESS NewswireGENEVA, SWITZERLAND / ACCESSWIRE / April 1, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, rep
4y agoNRXP RLFTF RLFTYRelief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19ACCESS NewswireGENEVA, SWITZERLAND / ACCESSWIRE / April 1, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, rep
4y agoNRXP RLFTF RLFTYRelief Reports Full-Year 2021 Results and Provides Corporate UpdateACCESS NewswireGENEVA, SWITZERLAND / ACCESSWIRE / March 31, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, toda
4y agoRLFTF RLFTYRelief Therapeutics Reports In Vivo Data Indicating Prolonged Release of Amino Acids Using its Physiomimic(TM) Technology May Have Benefits for the Treatment of PKUACCESS NewswireRelief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports In Vivo Data Published in the Peer Reviewed, International Journal of Molecular Sciences, Indicating Prolonged Release of Amino Acids Using Its PhysiomimicTM Technology Ma
4y agoRLFTF RLFTYRelief Receives Trademark Registration for RLF-100(R) From the U.S. Patent and Trademark OfficeACCESS NewswireGENEVA, SWITZERLAND / ACCESSWIRE / March 24, 2022 / RELIEF THERAPEUTICS Holding SA ((SIX:RLF, OTCQB:RLFTF, RLFTY)) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today
4y agoRLFTF RLFTYRelief Therapeutics Appoints Christopher Wick as Senior Director, Head of U.S. SalesACCESS NewswireProven Pharmaceutical Sales Professional Brings Big Pharma Experience to Relief's U.S. Expansion Activities GENEVA, SWITZERLAND / ACCESSWIRE / March 21, 2022 / RELIEF THERAPEUTICS Holding SA ((SIX: RLF, OTCQB:RLFTF, RLFTY)) (" Relief "), a biopharmaceut
4y agoRLFTF RLFTYRelief Therapeutics Files Amendment No. 1 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange CommissionACCESS NewswireGENEVA, SWITZERLAND / ACCESSWIRE / March 21, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), announced today that it has filed Amendment No. 1 to its Registration Statement on Form 20-F ("Registration Statement") wi
4y agoRLFTF RLFTYRelief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS-CoV-2 Infected PatientsACCESS NewswireDespite Primary Endpoint not Being Met, Due to Small Sample Size, Results Show a Very Positive Trend in Efficacy Parameters with a Clean Safety and Tolerability Profile GENEVA, SWITZERLAND / ACCESSWIRE / March 17, 2022 / RELIEF THERAPEUTICS Holding SA (